文献速递瓣膜外科

65岁及以上患者外科与经导管主动脉瓣置换对比

Surgical vs Transcatheter Aortic Valve Replacement in Patients 65 Years of Age and Older.
PubMed 文献 · Ann Thorac Surg · 2025-02-25

基于美国Medicare数据库2018-2022年数据,评估65-85岁首次单纯行SAVR(n=34,215)或TAVR(n=124,897)的患者。按预测风险分层后,SAVR在各风险层院内死亡率、急性肾损伤和出血更高但起搏器率更低;低中风险患者SAVR的5年复合终点(死亡、卒中或瓣膜再干预)更优。

要点

  • 低中危患者SAVR的5年无死亡、卒中或再干预生存优于TAVR。
  • 各风险层SAVR院内死亡率、急性肾损伤和出血高于TAVR。
  • SAVR起搏器植入率低于TAVR。

核心结论

  • 在低危和中危Medicare受益者中,SAVR与较高的院内死亡率相关,但5年无死亡、卒中或瓣膜再干预生存优于TAVR。

研究设计与样本

  • 基于美国Centers for Medicare Services数据库的回顾性队列研究,纳入2018-2022年65-85岁首次单纯SAVR(n=34,215)或TAVR(n=124,897)患者。
  • 采用逆概率加权和多层回归竞争风险时间-事件分析进行双重稳健风险调整。
  • 按模拟STS预测手术死亡率并纳入衰弱的预测风险分为低危(<4%)、中危(4%-8%)和高危(>8%)三层。

主要发现

  • 各风险层SAVR的院内死亡率、急性肾损伤和出血均高于TAVR(均P < .05)。
  • 各风险层SAVR起搏器植入率低于TAVR(P < .05)。
  • 低危患者SAVR的5年复合终点(死亡、卒中或瓣膜再干预)HR 0.85(P = .044)。
  • 中危患者SAVR的5年复合终点HR 0.86(P = .039)。
  • 低危患者卒中再入院HR 0.72(P = .038),中危患者HR 0.78(P = .042)。

临床怎么用

  • 心脏团队决策时应综合考虑:低中危患者SAVR虽院内结局较差但5年复合终点更优,需结合患者偏好与风险评估个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approval of transcatheter aortic valve replacement (TAVR) for all risk profiles has extended TAVR use in patients not otherwise examined in clinical trials. We sought to evaluate contemporary real-world outcomes of surgical aortic valve replacement (SAVR) vs TAVR in Medicare beneficiaries by risk strata. METHODS: Using the US Centers for Medicare Services database, all patients aged 65-85 years undergoing isolated first-time SAVR (n = 34,215) or TAVR (n = 124,897) were evaluated (2018-2022). Predicted patient risk accounting for comorbidities simulating The Society of Thoracic Surgeons predicted risk of surgical mortality, but including frailty, were stratified by low (<4%, n = 36,297 TAVR; n = 14,693 SAVR), intermediate (4%-8%, n = 44,026 TAVR; n = 9693 SAVR), or high (>8%, n = 44,574 TAVR; n = 9841 SAVR) risk. Doubly robust risk adjustment with inverse probability weighting and multilevel regression with competing-risk time-to-event analyses compared outcomes. RESULTS: SAVR was associated with higher risk-adjusted in-hospital mortality, acute kidney injury, and bleeding but lower pacemaker rate compared with TAVR across all risk strata (all P < .05). Longitudinal 5-year analysis highlighted that, compared with TAVR, SAVR was associated with superior freedom from composite death, stroke, or valve reintervention in low- and intermediate-risk patients (hazard ratio [HR] 0.85, P = .044, and HR 0.86, P = .039, respectively) as well as lower overall readmission for stroke in low- (HR 0.72, P = .038) and intermediate- (HR 0.78, P = .042) risk patients. CONCLUSIONS: In low- and intermediate-risk Medicare beneficiaries, SAVR was associated with higher in-hospital mortality but superior 5-year longitudinal freedom from death, stroke, or valve reintervention compared to TAVR. These data may further enhance heart team decision-making and patient counseling.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wolfe S, Jagadeesan V, Wei L, et al. Surgical vs Transcatheter Aortic Valve Replacement in Patients 65 Years of Age and Older. Ann Thorac Surg. 2025. PMID: 40015547. doi:10.1016/j.athoracsur.2025.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。